article thumbnail

EVERSANA Expands Global Commercialisation Capabilities and Strengthens Agency Network with Healthware Group Acquisition

Digital Health Global

The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.

article thumbnail

Trust in Healthcare is Under Stress in the US and Globally, Edelman Finds

Health Populi

Year-on-year, different spikes and ups-and-downs call out for special mention, such as: Pharma’s 13-point steep dive to 38% between 2017 and 2018, dramatically recovering by 9 points in the last year to 47% [with the wild card here of whether U.S. to approve Medicare’s negotiation of drug prices with pharmaceutical companies].

BioTech 310
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Americans’ Trust in the Healthcare System Low Compared to Rest-of-World’s Health Citizens

Health Populi

Among these people, healthcare trust fell by 20 percentage points between 2017 and 2018, a “crash” (Edelman’s descriptor) from 75 percent to 55%. Biotech is roughly tied for second place with consumer health, dropping also by 7 points. In that context, look at chart #4, “Biotech Seen as the Laboratory vs Pharma.”

BioTech 185
article thumbnail

Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology

Healthcare IT Today

Founded in 2017 as an AI research company, Unlearn has always been at the forefront of developing innovative AI-based solutions for clinical trials. Unlearn’s technology powers the clinical trials of leading global pharmaceutical companies, helping them to reach full enrollment faster and bring new treatments to patients sooner.

article thumbnail

Moderna, one of the biggest gambles in Biotech history to be tested on Wall Street with $10Bn IPO

Lloyd Price

One of the biggest gambles in biotech history is about to be tested on Wall Street. In its prospectus, Moderna set an initial target of $500 million for the offering, which would make it the largest biotech IPO in history. Unlike a typical biotech going public, Moderna has a pipeline of 21 programs, 10 of which are in human testing.

BioTech 52
article thumbnail

Patients and Industry: Starting Our New Life Together in 2023

Society for Participatory Medicine

Our honeymoon commenced in April with what some pharmaceutical sponsors refer to as a “mandate” to show proof of a diversity, equity, and inclusion plan “as soon as practical” in the new drug application process, further solidified by the passage of the omnibus spending package at the end of 2022.

BioTech 144
article thumbnail

Asia HealthTech Investment 2018 Report

Lloyd Price

Significantly exceeding 2017 in $ size, and doubling 2016, the Asia ecosystem is fast catching the US. HealthTech does not include Biotech, such as protein research or pharmaceuticals, and also does not include MedDev, such as devices that are implanted into the body. Source : [link]

BioTech 56